Gary Gerstenblith

Gary Gerstenblith

Auto-generated profile, based on publicly available information

Gary Gerstenblith

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , Halsted 500, Baltimore, MD 21287

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Circulation
Verified
Journal Article
Open access
ADAbdulla A. Damluji
Abdulla A. Damluji
MAMaha Alfaraidhy
Maha Alfaraidhy
NANoora Alhajri
Noora Alhajri
NRNamit N. Rohant
Namit N. Rohant
MKManish Kumar
Manish Kumar
PGParag Goyal
Parag Goyal
Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by chronic comorbidities including cardiovascular diseases, chronic kidney disease, and cancer. Sarcopenia is associated with faster progression of cardiovascular diseases and higher risk of mortality, falls, and reduced quality of life, particularly among older adults. Although the pathophysiologic mechanisms are complex, the broad underlying cause of sarcopenia includes an imbalance between anabolic and catabolic muscle homeostasis with or without neuronal degeneration. The intrinsic molecular mechanisms of aging, chronic illness, malnutrition, and immobility are associated with the development of sarcopenia. Screening and testing for sarcopenia may be particularly important among those with chronic disease states. Early recognition of sarcopenia is important because it can provide an opportunity for interventions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascular outcomes. Relying on body mass index is not useful for screening because many patients will have sarcopenic obesity, a particularly important phenotype among older cardiac patients. In this review, we aimed to: (1) provide a definition of sarcopenia within the context of muscle wasting disorders; (2) summarize the associations between sarcopenia and different cardiovascular diseases; (3) highlight an approach for a diagnostic evaluation; (4) discuss management strategies for sarcopenia; and (5) outline key gaps in knowledge with implications for the future of the field.

28 July 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
TLThorsten M. Leucker
Thorsten M. Leucker
MBMichael J. Blaha
Michael J. Blaha
SJSteven R. Jones
Steven R. Jones
MVMichael A. Vavuranakis
Michael A. Vavuranakis
MWMarlene S. Williams
Marlene S. Williams
GGGary Gerstenblith
Gary Gerstenblith

21 July 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TLThorsten M. Leucker
Thorsten M. Leucker
GGGary Gerstenblith
Gary Gerstenblith
MSMichael Schär
Michael Schär
TBTodd T. Brown
Todd T. Brown
SJSteven R. Jones
Steven R. Jones
AHAllison G. Hays
Allison G. Hays
Background: PCSK9 (proprotein convertase subtilisin/kexin type 9) is well recognized for its important role in cholesterol metabolism. Elevated levels are associated with increased cardiovascular risk and inhibition with PCSK9 antibodies (PCSK9i) lowers cardiovascular events in patients with coronary artery disease. PCSK9 levels are also elevated in people living with HIV (PLWH) and those with dyslipidemia. Because increased PCSK9 in PLWH is associated with impaired coronary endothelial function, a barometer of coronary vascular health, we tested the hypothesis that PCSK9i improves impaired coronary endothelial function in dyslipidemia without coronary artery disease and in PLWH with nearly optimal/above goal low‐density lipoprotein cholesterol levels. Methods and Results: We performed a single‐center study in 19 PLWH and 11 with dyslipidemia to evaluate the effects of the PCSK9i evolocumab on coronary endothelial function using cine 3T MRI to noninvasively measure coronary endothelial function, assessed as the changes in coronary cross‐sectional area and coronary blood flow from rest to that during isometric handgrip exercise, a known endothelial‐dependent vasodilator. Before evolocumab, there was a decrease or no coronary vasodilation and no increase in coronary blood flow (the normal responses) to isometric handgrip exercise in either group. Following 6 weeks of evolocumab, 480 mg q4 weeks, the % cross‐sectional area changes from rest to isometric handgrip exercise were +5.6±5.5% and +4.5±3.1% in the PLWH and dyslipidemia groups, respectively, both P <0.01 versus baseline. Improved cross‐sectional area was paralleled by a significant coronary blood flow improvement in both groups. Conclusions: To our knowledge, these data represent the first evidence that PCSK9 inhibition improves coronary artery health in PLWH and people with dyslipidemia. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03500302.

20 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
NINaila Ijaz
Naila Ijaz
YJYasser Jamil
Yasser Jamil
CBCharles H. Brown
Charles H. Brown
AKAshok Krishnaswami
Ashok Krishnaswami
AOAriela R Orkaby
Ariela R Orkaby
ADAbdulla A. Damluji
Abdulla A. Damluji
As the older adult population expands, an increasing number of patients affected by geriatric syndromes are seen by cardiovascular clinicians. One such syndrome that has been associated with poor outcomes is cognitive frailty: the simultaneous presence of cognitive impairment, without evidence of dementia, and physical frailty, which results in decreased cognitive reserve. Driven by common pathophysiologic underpinnings (eg, inflammation and neurohormonal dysregulation), cardiovascular disease, cognitive impairment, and frailty also share the following risk factors: hypertension, diabetes, obesity, sedentary behavior, and tobacco use. Cardiovascular disease has been associated with the onset and progression of cognitive frailty, which may be reversible in early stages, making it essential for clinicians to diagnose the condition in a timely manner and prescribe appropriate interventions. Additional research is required to elucidate the mechanisms underlying the development of cognitive frailty, establish preventive and therapeutic strategies to address the needs of older patients with cardiovascular disease at risk for cognitive frailty, and ultimately facilitate targeted intervention studies.

15 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
SLSabra C. Lewsey
Sabra C. Lewsey
KWKilian Weiss
Kilian Weiss
MSMichael Schär
Michael Schär
YZYi Zhang
Yi Zhang
PBPaul A. Bottomley
Paul A. Bottomley
RWRobert G. Weiss
Robert G. Weiss
BACKGROUND: Physical frailty in older individuals is characterized by subjective symptoms of fatigue and exercise intolerance (EI). Objective abnormalities in skeletal muscle (SM) mitochondrial high-energy phosphate (HEP) metabolism contribute to EI in inherited myopathies; however, their presence or link to EI in the frail older adult is unknown. METHODS: Here, we studied 3 groups of ambulatory, community-dwelling adults with no history of significant coronary disease: frail older (FO) individuals (81 ± 2.7 years, mean ± SEM), nonfrail older (NFO) individuals (79 ± 2.0 years), and healthy middle-aged individuals, who served as controls (CONT, 51 ± 2.1 years). Lower extremity SM HEP levels and mitochondrial function were measured with 31 P magnetic resonance (MR) techniques during graded multistage plantar flexion exercise (PFE). EI was quantified by a 6-minute walk (6MW) and peak oxygen consumption during cardiopulmonary testing (peak VO 2 ). RESULTS: During graded exercise, FO, NFO, and CONT individuals all fatigued at similar SM HEP levels, as measured by 31 P-MR. However, FO individuals fatigued fastest, with several-fold higher rates of PFE-induced HEP decline that correlated closely with shorter exercise duration in the MR scanner and with 6MW distance and lower peak oxygen consumption on cardiopulmonary testing ( P < 0.001 for all). SM mitochondrial oxidative capacity was lower in older individuals and correlated with rapid HEP decline but less closely with EI. CONCLUSION: Several-fold faster SM energetic decline during exercise occurs in FO individuals and correlates closely with multiple measures of EI. Rapid energetic decline represents an objective, functional measure of SM metabolic changes and a potential new target for mitigating frailty-associated physical limitations. FUNDING: This work was supported by NIH R21 AG045634, R01 AG063661, R01 HL61912, the Johns Hopkins University Claude D. Pepper Older Americans Independence Center P30AG021334, and the Clarence Doodeman Endowment in Cardiology at Johns Hopkins.

31 August 2024 in European Heart Journal Open
Verified
Journal Article
Open access
PDF file
THTarek Harb
Tarek Harb
EZEfthymios Ziogos
Efthymios Ziogos
RBRoger S Blumenthal
Roger S Blumenthal
GGGary Gerstenblith
Gary Gerstenblith
TLThorsten M Leucker
Thorsten M Leucker
Aims: Lipoprotein(a) [Lp(a)] levels are predominantly genetically determined and repeat measurements are generally considered unlikely to be clinically useful. However, the temporal variation of Lp(a) is not well characterized. Our aim was to determine the intra-individual variability of Lp(a) and whether a repeated measure reclassified Lp(a)-specific cardiovascular risk using the European Atherosclerosis Society (EAS) consensus statement risk categories. Methods and results: This retrospective cohort study analysed initial and repeated serum Lp(a) levels measured using the same methodology from 609 individuals in the Nashville Biosciences database, a de-identified electronic medical records database. Baseline and follow-up paired values were significantly different (P < 0.05), with an absolute change of ≥10 mg/dL in 38.1% [95% CI 34.2–42%] and a >25% change in 40.5% [95% CI 36.6–44.3%] of individuals. Although the categories of those whose values were in the EAS low-risk and high-risk categories did not change, 53% of those in the intermediate ‘grey-zone’ category transitioned to either the low-risk (20%) or high-risk (33%) category. Black individuals exhibited greater variability than White individuals and women exhibited greater variability than men. There was a positive correlation between the baseline Lp(a) levels and the absolute changes in Lp(a), (r = 0.59, P < 0.01). Conclusion: Temporal-related changes in Lp(a) variability were present in many individuals. A repeat Lp(a) measure may allow more precise Lp(a)-specific cardiovascular risk prediction for individuals whose initial value is in the EAS-defined intermediate ‘grey-zone’ category. Lp(a) variability should be included in calculating the expected effect sizes in future clinical research studies targeting Lp(a).